EC grants marketing authorisation to BridgeBio's ATTR-CM treatment
The European Commission (EC) has granted marketing authorisation to BridgeBio Pharma's selective small molecule, acoramidis, under the brand name Beyonttra, for treating wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy (ATTR-CM).
An orally administered near-complete (≥90%) transthyretin (TTR) stabiliser, acoramidis is designed to combat this progressive fatal disease, which can lead to heart failure.
The approval in the European Union (EU) is based on outcomes from the Phase III ATTRibute-CM trial of the therapy, which demonstrated cardiovascular benefits.
The study involved 632 subjects with symptomatic ATTR-CM and met its primary clinical endpoints at month 30.
It showed a significant decrease in cardiovascular-related hospitalisation, improved survival rates, preserved functional capacity and better quality of life for individuals.
BridgeBio Cardiorenal chief medical officer Dr Jonathan Fox stated: 'The EU approval of acoramidis is a significant advancement for patients living with ATTR-CM in need of new disease-modifying treatments for their condition.
'This approval would not have been possible without the commitment of the clinical trial participants and their families, and the dedicated support of the physicians and scientists involved in the clinical programme.'
Bayer, responsible for all commercial activities for the therapy in the EU, is set to launch Beyonttra in the first half of 2025.
BridgeBio and Bayer initiated a partnership for the therapy in March 2024, granting the latter exclusive commercialisation rights in the EU.
Acoramidis is also under review for approval by the Brazilian Health Regulatory Agency and the Japanese Pharmaceuticals and Medical Devices Agency.
The latest development follows the therapy's approval under the name of Attruby by the US Food and Drug Administration in November 2024 to treat adults with ATTR-CM.
"EC grants marketing authorisation to BridgeBio's ATTR-CM treatment" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
30 minutes ago
- Business Wire
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
BERLIN & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bayer and the Broad Institute today announced that they have extended their research collaboration of 10 years by an additional five years, to further advance findings in human genomics research in cardiovascular diseases. The expanded agreement will focus on joint precision cardiology target identification, leveraging the established human cardiomyocyte platform to rapidly validate observations, and discovery of novel therapeutic approaches. Current efforts are directed to develop potential treatment options for patients with specific forms of cardiovascular disease such as dilated cardiomyopathy (DCM), amongst others. DCM is a type of heart disease characterized by the enlargement of the heart's chambers, which leads to a decreased ability to pump blood effectively. This condition can result in heart failure and other complications if left untreated. 1 Established in 2013, this longstanding collaboration combines the Broad Institute's extensive expertise in genomics and biology with Bayer's in-depth experience in small, chemically manufactured molecules and biologics drug discovery to advance drug discovery research for novel cardiovascular therapeutics. This strategic research alliance already has resulted in a number of joint publications and conference presentations, and it has paved the way for Bayer's announcement in May 2025 regarding the initiation of a Phase I study with its investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor which has a potential to help control the electrical activity of heart cells in patients with atrial fibrillation (AFib). 'We are constantly evaluating novel approaches to treat cardiovascular diseases that affect millions of people worldwide. Our shared commitment is to explore novel therapeutic targets and modalities in various cardiovascular and renal diseases to help deliver new treatment options to patients in need,' said Andrea Haegebarth, Ph.D., Global Head of Research and Early Development for Cardiovascular, Renal, and Immunology at Bayer's Pharmaceuticals Division. 'The first joint therapeutic project entered the clinic last month and we are excited to collaborate further with the esteemed scientists at the Broad Institute to identify and develop disease-modifying therapeutics treating underlying causes of cardiovascular diseases.' 'I am delighted to see Broad and Bayer continue this fruitful collaboration in cardiovascular research,' said Todd Golub, director and founding core member of the Broad Institute. 'By working together, Broad and Bayer are able to make advances that neither organization could make on its own.' Academic collaborations are integral to Bayer's research and development strategy, aimed at delivering innovative treatment solutions to patients, particularly in areas with significant unmet medical needs, such as cardiovascular health. Bayer's strategic focus in cardiovascular research emphasizes precision drug development, facilitating the rapid identification of the most promising targets and commercially viable programs. Bayer with its Bayer Research & Innovation Center (BRIC) is closely located to the Broad Institute in Kendall Square, Cambridge, MA. BRIC houses a center of precision oncology research as well as an experienced team of scientists focused on research and early development for developing precision cardiovascular, renal, and immunology therapeutics. BRIC is also home to Bayer Cambridge which is part of a pioneering global network of life science incubators focused on disruptive innovation and scientific breakthroughs. Financial details have not been disclosed. About Bayer's Commitment in Cardiovascular Diseases Bayer is a leader in cardiology and is advancing a portfolio of innovative treatments in cardiovascular (CV) diseases of high unmet medical need. The strategy is to unlock the strong potential of the future CV market by transforming Bayer's portfolio into precision cardiology, addressing the high CV disease burden, and driving the long-term growth. Bayer's portfolio already includes several innovative products as well as compounds in various stages of preclinical and clinical development. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to aka (2025e-0114) Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Yahoo
33 minutes ago
- Yahoo
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
Focus on joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases Current efforts focused on treatment options for specific forms of cardiovascular disease such as dilated cardiomyopathy Phase I clinical study in healthy volunteers for development of new treatment for patients with atrial fibrillation recently initiated Extended collaboration to further strengthen Bayer's precision cardiology pipeline BERLIN & CAMBRIDGE, Mass., June 11, 2025--(BUSINESS WIRE)--Bayer and the Broad Institute today announced that they have extended their research collaboration of 10 years by an additional five years, to further advance findings in human genomics research in cardiovascular diseases. The expanded agreement will focus on joint precision cardiology target identification, leveraging the established human cardiomyocyte platform to rapidly validate observations, and discovery of novel therapeutic approaches. Current efforts are directed to develop potential treatment options for patients with specific forms of cardiovascular disease such as dilated cardiomyopathy (DCM), amongst others. DCM is a type of heart disease characterized by the enlargement of the heart's chambers, which leads to a decreased ability to pump blood effectively. This condition can result in heart failure and other complications if left untreated.1 Established in 2013, this longstanding collaboration combines the Broad Institute's extensive expertise in genomics and biology with Bayer's in-depth experience in small, chemically manufactured molecules and biologics drug discovery to advance drug discovery research for novel cardiovascular therapeutics. This strategic research alliance already has resulted in a number of joint publications and conference presentations, and it has paved the way for Bayer's announcement in May 2025 regarding the initiation of a Phase I study with its investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor which has a potential to help control the electrical activity of heart cells in patients with atrial fibrillation (AFib). "We are constantly evaluating novel approaches to treat cardiovascular diseases that affect millions of people worldwide. Our shared commitment is to explore novel therapeutic targets and modalities in various cardiovascular and renal diseases to help deliver new treatment options to patients in need," said Andrea Haegebarth, Ph.D., Global Head of Research and Early Development for Cardiovascular, Renal, and Immunology at Bayer's Pharmaceuticals Division. "The first joint therapeutic project entered the clinic last month and we are excited to collaborate further with the esteemed scientists at the Broad Institute to identify and develop disease-modifying therapeutics treating underlying causes of cardiovascular diseases." "I am delighted to see Broad and Bayer continue this fruitful collaboration in cardiovascular research," said Todd Golub, director and founding core member of the Broad Institute. "By working together, Broad and Bayer are able to make advances that neither organization could make on its own." Academic collaborations are integral to Bayer's research and development strategy, aimed at delivering innovative treatment solutions to patients, particularly in areas with significant unmet medical needs, such as cardiovascular health. Bayer's strategic focus in cardiovascular research emphasizes precision drug development, facilitating the rapid identification of the most promising targets and commercially viable programs. Bayer with its Bayer Research & Innovation Center (BRIC) is closely located to the Broad Institute in Kendall Square, Cambridge, MA. BRIC houses a center of precision oncology research as well as an experienced team of scientists focused on research and early development for developing precision cardiovascular, renal, and immunology therapeutics. BRIC is also home to Bayer Cambridge which is part of a pioneering global network of life science incubators focused on disruptive innovation and scientific breakthroughs. Financial details have not been disclosed. About Bayer's Commitment in Cardiovascular Diseases Bayer is a leader in cardiology and is advancing a portfolio of innovative treatments in cardiovascular (CV) diseases of high unmet medical need. The strategy is to unlock the strong potential of the future CV market by transforming Bayer's portfolio into precision cardiology, addressing the high CV disease burden, and driving the long-term growth. Bayer's portfolio already includes several innovative products as well as compounds in various stages of preclinical and clinical development. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to Find more information at Follow us on Facebook: ________________________ 1 Ferreira A, Ferreira V, Antunes MM, Lousinha A, Pereira-da-Silva T, Antunes D, Cunha PS, Oliveira M, Ferreira RC, Rosa SA. Dilated Cardiomyopathy: A Comprehensive Approach to Diagnosis and Risk Stratification. Biomedicines. 2023 Mar 9;11(3):834. doi: 10.3390/biomedicines11030834. PMID: 36979813; PMCID: PMC10044994. aka (2025e-0114) Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. View source version on Contacts Bayer Global Media Contact:Derin Denham, phone +1 973 610 7324 Email: Bayer U.S. Media Contact:Elaine Colon, phone +1 732 236 1587 Email: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Mapping Ireland's peatlands to help cut carbon emissions
Mapping more accurately than ever Ireland's peatlands, which are vital as carbon sinks but whose boundaries can be hard to determine, could help fight global warming, researchers say. Ireland is pockmarked with patches of dark brown peat soil that make up at least 20 percent of the land cover, according to Eve Daly, a geophysicist at the University of Galway, who co-led a groundbreaking project on finding peat. "Peatland soils contain comparable amounts of carbon to the likes of rainforests so a more accurate map can lead to better land management decisions and mitigate against greenhouse gas emissions," Daly told AFP. Her research team developed a new mapping approach using gamma radiation measurements to identify for the first time "transition zones" -- typically hidden under forests and grasslands -- where the soil changes from being peat to mineral-based. Daly says the area of soil in Ireland considered "peaty" has increased thanks to a new colour-coded "peat/non-peat" map produced by the researchers. "Improved mapping at higher resolution and locating where hidden organic peat soils are and their extent are key inputs into working out carbon emission factors," she said. Her project co-leader Dave O'Leary told AFP about 80 percent of Ireland had now been mapped out in patches of "peat" brown or "non-peat" green. "Few countries have invested in such an incredible data set, which puts Ireland at the forefront of peatland mapping research," he said. - 'New lens' - Land use, including farming and peatland draining, is a major source of Ireland's carbon emissions which could see the country failing to meet an EU-agreed climate target to cut emissions by over 50 percent by 2030. A recent report said Ireland risks an EU fine of almost 30 billion euros if it fails to reach the target and recommended the restoring -- and rewetting -- of thousands of hectares of peatlands to help deliver "massive" cuts in emissions. "We need to use more modern technologies or use old technologies with new lenses to try and find these hidden peat soils," Daly said. Ireland's boggy areas are typically located in the middle of the bowl-shaped country which is ringed with hills and low mountains around the coastal areas. Triven Koganti, an agroecology expert at Denmark's Aarhus University, told AFP that five percent of global greenhouse gas emissions came from cultivated peatlands. "Historical agricultural draining of peatlands... or to use them as a fuel source has led to significant greenhouse gas emissions," he said. So "an accurate accounting" of peatland boundaries is needed to achieve "current global initiatives to restore peatlands", he said, adding the Irish research "plays an important role in establishing this". - 'Bird's eye' technique - The mapping technique -- described as "bird's eye" by Daly -- is based on gamma-ray data measured by a sensor onboard a plane that has been flown low over Ireland for a decade in a state-funded geophysical survey. "All rocks and different amounts of soils give off a certain amount of natural radiation but peat doesn't as it's full of organic material," Daly said. Soils are usually a mixture of broken bits of rock, water and air, but peat soils are distinct from mineral soils as they are formed from decaying plant material, water and air, and contain a very high amount of carbon. When waterlogged, this carbon is stored in the soil but when water is removed, for example via drainage, peat soils then emit carbon dioxide as the decay process restarts, Daly said. The state-funded "Tellus" survey began in 2011 and is expected to be completed later this year. pmu/jkb/giv/dhw
